Wet age-related macular degeneration
Conditions
Interventions
3+PRN group:Initially, the drug was administered once a month, followed up every month after 3 consecutive times, and treated as needed
T&E group:Initially, the drug was administered once a month, followed up every month after three consecutive times until the retinal exudation was controlled, and then the interval of the next follow-
Sponsors
Xi'an NO.1 Hospital (The First Affiliated Hospital of Northwestern University)
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with w-AMD, aged >= 50 years, regardless of gender; 2.Patients can sign informed consent for treatment and can follow up according to the agreement of clinical research; 3.Best Corrected Vision (ETDRS): (1) 19 letters <= BCVA <= 73 letters (equivalent to Snellen visual acuity: 20/400 <= BCVA <= 20/40), intraocular pressure (IOP) <= 21mmHg; (2) OCTA examination indicated choroidal neovascularization and exudation between retinal layers; (3) ICGA/FFA indicated choroidal neovascularization and fluorescein leakage. 4.Patients who are willing to sign informed consent and can follow up for a long time.
Exclusion criteria
Exclusion criteria: 1.There are eyelid ectropion, conjunctivitis, keratitis, dacryocystitis and other ocular surface diseases; 2.Received intravitreal, periocular or systemic anti VEGF or cortical sterol treatment within 6 months; 3.The target eye underwent intraocular or periocular surgery and received PDT and retinal laser photocoagulation within 6 months; 4.The target eye has other eye diseases and diseases affecting BCVA or is taking oral drugs affecting BCVA; 5.Patients with poor blood glucose control and poorly controlled blood pressure; 6.Patients with a history of myocardial infarction or cerebral infarction; There are confirmed systemic immune diseases or other systemic diseases such as AIDS, active hepatitis, severe mental, neurological, cardiovascular, respiratory diseases, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-corrected visual acuity (BCVA);Thickness of central retina of macula;Area of neovascular;Vascular endothelial growth factor-related protein; | — |
Secondary
| Measure | Time frame |
|---|---|
| Macular pigment density;Intraocular pressure; | — |
Countries
China
Contacts
Public ContactChen Xiaodong
Xi'an NO.1 Hospital (The First Affiliated Hospital of Northwestern University)
Outcome results
None listed